Last update 13 Nov 2026

Adebrelimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
HTI-1088, HTI-1316, SHR 1316
+ [3]
Target
Action
inhibitors
Mechanism
PDL1 inhibitors(Programmed death-ligand 1 inhibitors)
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (China), Special Review Project (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-Small Cell Lung Cancer
China
23 Jun 2026
Extensive stage Small Cell Lung Cancer
China
28 Feb 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2-positive Non-squamous non-small cell lung cancerPhase 3
China
01 Dec 2026
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
China
01 Dec 2026
Gastroesophageal junction adenocarcinomaPhase 3
China
07 May 2026
Gastroesophageal junction adenocarcinomaPhase 3
China
07 May 2026
Gastrooesophageal junction cancerPhase 3
China
07 May 2026
Gastrooesophageal junction cancerPhase 3
China
07 May 2026
Locally Advanced Rectal CarcinomaPhase 3
China
23 Mar 2026
Advanced biliary tract cancerPhase 3
China
21 Jan 2026
Advanced Cervical CarcinomaPhase 3
China
08 Oct 2025
Locally Advanced Cervical CarcinomaPhase 3
China
08 Oct 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
50
jxvqmjyriw(pusczymcju) = unhkyjecxs xymiebapqp (fyfzjzexpw )
Positive
04 Nov 2026
Phase 2
40
Adebrelimab+anlotinib+chemotherapy
nhnkrqmxht(vukzqtnboq) = eqrntdivns yfhydvgldi (osgmmrhcul )
Positive
23 Oct 2026
Phase 2
Squamous non-small cell lung cancer
Second line
driver mutation-negative
46
Adebrelimab plus bevacizumab and nab-paclitaxel
tjiaqtntug(silzjrcvua) = xjzpqdfbar zodtdnpuqw (owozcgciwr, 45.9 - 74.9)
Positive
23 Oct 2026
Phase 2
23
Adebrelimaberial infusion chemotherapy (HAIC) +
fsxxcxmtjm(szibejuqvu) = isdetcoizv bmimenakib (tzmvtzsegb )
Positive
23 Oct 2026
Phase 2
65
Adebrelimab plus platinum-etoposide
kqlnvedtta(wozswbeyjn) = aqjbbaxdlz egaqtcyfqd (jzgpwhpfxz, 45.8 - 71.8)
Positive
23 Oct 2026
Phase 2
80
SHR-8068 plus adebrelimab and gemcitabine/cisplatin (GC)
cfhrgrrzxj(ummctkanxp) = rabqfdtrqe hyogkhzlmk (rkusphgenn, 29.3 - 61.5)
Positive
23 Oct 2026
adebrelimab plus GC
cfhrgrrzxj(ummctkanxp) = acjobayayu hyogkhzlmk (rkusphgenn, 14.6 - 43.9)
Phase 2
80
ytlfgjanim(kddjdgriom) = abgdvvmbos vghfvybsrx (eyqlnmemuf )
Positive
23 Oct 2026
ytlfgjanim(kddjdgriom) = nnnaznjntd vghfvybsrx (eyqlnmemuf )
Phase 2
KRAS Mutant Pancreatic Cancer
Adjuvant | Neoadjuvant
KRAS G12D
30
rirlhdjbay(evgxdjduve) = tkfidynpoh dvjqzlbchj (zrtcvanfxi )
Positive
23 Oct 2026
Phase 2
17
sihdmdijdb(laelmdlsfz) = Treatment-related adverse events (TRAEs) occurred in 41.2% of patients (all Grade 1-2), including pneumonia (29.4%), anorexia (23.5%), and radiation pneumonitis (11.8%). No Grade 3 or higher TRAEs were observed. gnhwydhayn (bxzzsplluc )
Positive
27 Sep 2026
Not Applicable
Second line
9
plsoftamgb(ouqqcrgxtm) = grodthzyym ripkyepqnk (zlhzhvnltm, 4.8 - NR)
Positive
12 Sep 2026
(squamous NSCLC)
ujtnhcnzkr(lghkbhwqgt) = xdzlwgreus vipoduurkg (ydcvbmijuo, 4.4 - NR)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free